BLRX – biolinerx ltd. - american depositary shares (US:NASDAQ)

News

BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.
BioLineRx to Report Third Quarter 2024 Results on November 25, 2024
BioLineRx Ltd. (NASDAQ: BLRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
BioLineRx Ltd. (NASDAQ: BLRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com